Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...
Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...
Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 32,455 put options on the company. This represents an increase of ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Jones Financial Companies Lllp boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.2% in the 4th quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback